Management of patients with malignancies and secondary immunodeficiencies treated with immunoglobulins in clinical practice: Long-term data of the SIGNS study
Management of patients with malignancies and secondary immunodeficiencies treated with immunoglobulins in clinical practice: Long-term data of the SIGNS study
复制标题
DOI：
10.1111/ejh.12900
复制
发表时间：
2017-08-01
影响因子：
3.1
通讯作者：
Hensel, Manfred
中科院分区：
文献类型：
--
作者：
Reiser, Marcel;Borte, Michael;Hensel, Manfred
我们的目的是描述目前的管理和结果的继发性免疫缺陷（SID）的患者静脉注射（IV）或皮下注射（SC）免疫球蛋白（IG）作为维持治疗，以防止感染。结果307例SID患者中，（平均年龄63.7 ± 14.4岁，52%为男性，31%为新开始的IG），95.4%接受IV IG（平均给药间隔4.6周，平均剂量199 mg/kg/4周）和4.6%接受SC IG治疗（2.6周，343 mg/kg/4周）。首次记录时至水平的中位IG为5.8 g/L，IV和SC治疗之间或基础恶性肿瘤之间无差异。24.1%的患者暂时中断治疗，平均中断时间为11.6 +/-6.3个月。结论在临床实践条件下，IG替代治疗SID患者是可行的，可降低感染率，提高生活质量。平均IG剂量相对较低。IV IG治疗的耐受性极好。
ObjectiveWe aimed to describe the current management and outcomes of patients with secondary immunodeficiencies (SID) on intravenous (IV) or subcutaneous (SC) immunoglobulins (IG) as maintenance therapy to prevent infections.MethodsNon-interventional, prospective study (average follow-up 20.5months).ResultsOf the 307 SID patients (mean age 63.714.4years, 52% males, in 31% IG newly initiated), 95.4% received IV IG (mean dosing interval 4.6weeks, average dose 199mg/kg per 4weeks) and 4.6% were treated with SC IG (2.6weeks, 343mg/kg per 4weeks). Median IG through level at first documentation was 5.8g/L and did not differ between IV and SC treatment or between underlying malignancies. In 24.1% of patients, treatment was interrupted temporarily, over a mean of 11.6 +/- 6.3months. In patients with newly initiated IG treatment the 82% overall infection rate prior to treatment dropped to 21% at 1year.ConclusionsUnder clinical practice conditions, IG replacement therapy in SID patients was feasible, diminished infection rates and improved quality of life. Average IG doses were relatively low. Tolerability of IV IG treatment was excellent.